Literature DB >> 16643212

Insight into molecular changes of the FIX protein in a series of Italian patients with haemophilia B.

M P Bicocchi1, M Pasino, C Rosano, A C Molinari, E Della Valle, T Lanza, F Bottini, M Acquila.   

Abstract

Deficiency or dysfunction of factor IX FIX leads to haemophilia B (HB), an X-linked, recessive, bleeding disorder. On a molecular basis, HB is due to a heterogeneous spectrum of mutations spread throughout the F9 gene. In several instances, a cause-effect relation has been elucidated, in others predicted possibilities have been offered by crystallography inspection and by software-constructed models of the protein. The aim of this study was to contribute to the understanding of HB molecular pathology. The F9 missense mutations we identified in 21 unrelated Italian HB patients by direct sequencing of the whole F9 coding regions were inspected for the causative effect they provoked on the ensuing transcript, and on the protein structure. Each alteration was studied in order to: (i) characterize the defect on the basis of the nature of the mutation; (ii) identify the predicted defect that is induced in the gene and (iii) speculate about the potential, detrimental effects which upset the protein functionality through an idealized FIX model. The resulting data may further contribute to the comprehension of the mechanisms underlying the disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16643212     DOI: 10.1111/j.1365-2516.2006.01275.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  3 in total

1.  Mutation analysis of a cohort of US patients with hemophilia B.

Authors:  Tengguo Li; Connie H Miller; Jennifer Driggers; Amanda B Payne; Dorothy Ellingsen; W Craig Hooper
Journal:  Am J Hematol       Date:  2014-03-03       Impact factor: 10.047

Review 2.  Hemophilia B: molecular pathogenesis and mutation analysis.

Authors:  A C Goodeve
Journal:  J Thromb Haemost       Date:  2015-05-18       Impact factor: 5.824

3.  Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B.

Authors:  Barbara Dietrich; Alexandra Schiviz; Werner Hoellriegl; Frank Horling; Karima Benamara; Hanspeter Rottensteiner; Peter L Turecek; Hans Peter Schwarz; Friedrich Scheiflinger; Eva-Maria Muchitsch
Journal:  Int J Hematol       Date:  2013-09-24       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.